Each vial contains: Piperacillin Sodium USP equivalent to Piperacillin 2/ 4 g + Tazobactam Sodium equivalent to Tazobactam 0.25/ 0.5 g.
In the treatment of lower RTI/ UTI/ intra-abdominal infections, skin and skin structure infections, bacterial septicemia polymicrobic infection.
Piperacillin, a broad-spectrum penicillin, exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. Tazobactam sodium has little clinically relevant in vitro activity against bacteria due to its reduced affinity to penicillin-binding proteins.
Adolescents, Adults and the Elderly: The usual dose is 4 g piperacillin/ 0.5 g tazobactam given every 8 hours. For children with appendicitis and/or peritonitis the recommended Microtaz dosage is 100 mg piperacillin/12.5 mg tazobactam per kilogram of body weight, every 8 hours in paediatric patients 9 months of age and older. For paediatric patients 2 to 9 months of age, the recommended dosage is 80 mg piperacillin/10 mg tazobactam per kilogram of body weight, every 8 hours.
Microtaz is contraindicated in patients with a history of acute severe allergic reaction to any other beta-lactam active substances (e.g. cephalosporin, monobactam or carbapenem) and history of allergic reactions to beta-lactamase inhibitors.
If patients develop a skin rash, they should be monitored closely and piperacillin/tazobactam discontinued if lesions progress. Haematological effects (including bleeding, leukopenia and neutropenia) have occurred. Nephrotoxicity in critically ill patients has been observed; Clostridium difficile associated diarrhoea: evaluate patients if diarrhoea occurs.
Piperacillin and tazobactam cross the placenta in humans. However, there are insufficient data with piperacillin and/or tazobactam in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Piperacillin is excreted in human milk; tazobactam concentrations in human milk have not been studied. Safety and efficacy in pediatric patients less than 2 months of age have not been established.
Can significantly reduce tobramycin concentrations in hemodialysis patients. Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered unless the benefit outweighs the risk. Co-administration with vancomycin may increase the incidence of acute kidney injury. Monitor coagulation parameters in patients receiving Microtaz and heparin or oral anticoagulants. Microtaz may prolong the neuromuscular blockade of vecuronium and other non-depolarizing muscle relaxants. Monitor for adverse reactions related to neuromuscular blockade.
Diarrhea, constipation, nausea, headache and insomnia.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS